Welcome to SuperLan Chemical Co.,Ltd.
Home > Products > DNA Damage > DNA-PK > CC-115

CC-115

(CAS No:1228013-15-7)
CC-115 is a dual inhibitor of DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR), with potential antineoplastic activity.
CAS No:1228013-15-7
Molecular Weight(MW):336.35
Purity:99.00%
Specification:500MG;1G;5G;10G;50G;100G
Price and large packaging, please e-mail consultation:info@SuperLan-chem.com
QC Documents
 COA  MSDS  HPLC  NMR
ChemicalInfomation
CAS No: 1228013-15-7
Molecular formula(MF) C16H16N8O
Molecular Weight(MW): 336.35
Alias
Solubility
In vitro DMSO 67 mg/mL (199.19 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo
Biological Activity
Description CC-115 is a dual inhibitor of DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR), with potential antineoplastic activity.
Targets
DNA-PK [2] mTOR [2] PI3Kα [2]
0.013 μM 0.021 μM 0.852 μM
In vitro

CC-115 inhibits the DNA damage repair pathway and TORK in CLL cells and induces caspase-dependent cell death in resting CLL cells. It induces cell death with an IC50 of 0.51 µM. CC-115 reverts CD40-induced chemoresistance. CC-115 treatment significantly reduces induction of expression Mcl-1, Bfl-1, and Bcl-XL on CD40 stimulation in CLL cells. It also blocks proliferation of CLL cells. In healthy B cells, CC-115 induces cell death with an IC50 of 0.93 µM. CC-115 and NU7441 completely block the proliferation of CD4+ and CD8+ T cells. Taken together, CC-115 induces direct cytotoxicity and can block signaling pathways that are important for CLL survival, chemo-resistance and proliferation in the in the LN microenvironment[1].

In vivo CC-115 decreases lymphadenopathy in CLL patients[1]. CC-115 shows good in vivo PK profiles across multiple species with 53%, 76%, and ∼100% oral bioavailability in mouse, rat, and dog, respectively. CC-115 has favorable physicochemical and pharmacokinetic properties, demonstrates in vivo mTOR pathway inhibition and tumor growth inhibition, as well as a good in vitro and in vivo safety profile, suitable for clinical development[2].